Literature DB >> 25991492

[Budesonide foam for ulcerative proctitis and proctosigmoiditis].

O Bachmann1, S Nitschmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25991492     DOI： 10.1007/s00108-015-3721-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

1.  Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.

Authors:  V Gross; S Bar-Meir; A Lavy; O Mickisch; Z Tulassay; L Pronai; L Kupcinskas; G Kiudelis; J Pokrotnieks; A Kovács; M Faszczyk; A Razbadauskas; B Margus; M Stolte; R Müller; R Greinwald
Journal:  Aliment Pharmacol Ther       Date:  2006-01-15       Impact factor: 8.171

2.  [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].

Authors:  W Rufle; P Frühmorgen; W Huber; J M Kimmig
Journal:  Z Gastroenterol       Date:  2000-04       Impact factor: 2.000

3.  Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis.

Authors:  Simon Bar-Meir; Herma H Fidder; Mark Faszczyk; Gabriele Bianchi Porro; Giacomo C Sturniolo; Oliver Mickisch; Ralph Müller; Roland Greinwald; Yehuda Chowers; Volker Grobeta
Journal:  Dis Colon Rectum       Date:  2003-07       Impact factor: 4.585

4.  Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.

Authors:  Angela Hammond; Tilo Andus; Michael Gierend; Karl-Walter Ecker; Jurgen Scholmerich; Hans Herfarth
Journal:  Hepatogastroenterology       Date:  2004 Sep-Oct

5.  Topical therapy is underused in patients with ulcerative colitis.

Authors:  F Seibold; N Fournier; C Beglinger; C Mottet; V Pittet; G Rogler
Journal:  J Crohns Colitis       Date:  2013-04-06       Impact factor: 9.071
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.